Traders should monitor for preclinical data readouts in Q2 2026, which could catalyze investor interest if results show enhanced anti-tumor activity. However, given the early stage and lack of clinical data, near-term impact is likely limited.
Price Chart
Executive Summary
Actuate Therapeutics announced an expanded preclinical research initiative to evaluate its GSK-3β inhibitor elraglusib in combination with RAS-targeted therapies for difficult-to-treat cancers, particularly RAS-mutant tumors like pancreatic cancer. The company believes the combination may overcome resistance mechanisms and enhance clinical outcomes, with initial data expected in Q2 2026. This is a strategic development effort, not a clinical trial result or regulatory milestone.
Key Facts
- Actuate Therapeutics is launching preclinical studies combining elraglusib with RAS inhibitors.
- The goal is to overcome resistance in RAS-driven cancers, including pancreatic cancer, melanoma, and colorectal cancer.
- Initial preclinical data expected in Q2 2026, with additional results in 2H 2026.
- Elraglusib has been administered to over 500 patients and is in a Phase 2 trial for metastatic pancreatic cancer.
- No clinical data or financial figures were disclosed; this is a forward-looking research announcement.
Financial Impact
No immediate financial impact disclosed; potential long-term value if preclinical data support clinical development
Risk Factors
- Preclinical results may not translate to clinical benefit.
- Company faces going concern uncertainty with funding needs beyond Q2 2026.
- Combination strategy is speculative and dependent on third-party RAS inhibitors and collaborators.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251848 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | S-1/A | $0.5990 $0.5279 | ▲ +11.87% | ▲ +11.72% | $0.4750 (+20.70%) |
Oct 14, 2026 12d ago | S-1/A | $0.4342 $0.5622 | ▼ −29.48% | ▼ −29.03% | $0.4750 (−9.40%) |
Oct 6, 2026 20d ago | S-1 | $0.7240 $0.4340 | ▲ +40.06% | ▲ +39.07% | $0.4750 (+34.39%) |
Aug 12, 2026 10w ago | Institutional Cluster | $0.9699 $1.06 | ▼ −9.29% | ▼ −9.73% | $0.4750 (+51.03%) |
Jun 9, 2026 19w ago | Press Release | $2.01 $2.05 | ▲ +1.99% | ▼ −0.42% | $0.4750 (−76.37%) |
May 11, 2026 24w ago | 8-K | $2.89 $2.43 | ▼ −15.92% | ▼ −15.99% | $0.4750 (−83.56%) |
May 6, 2026 24w ago | DEFA14A | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.4750 (−84.11%) |
May 6, 2026 24w ago | 8-K | $2.99 $2.89 | ▼ −3.34% | ▼ −4.48% | $0.4750 (−84.11%) |
Apr 14, 2026 27w ago | Press Release | $2.08 $2.27 | ▲ +8.89% | ▲ +7.50% | $0.4750 (−77.16%) |
Mar 9, 2026 33w ago | Press Release | $2.95 $2.68 | ▼ −9.00% | ▼ −7.64% | $0.4750 (−83.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers